Cargando…

Development and evaluation of (89)Zr-trastuzumab for clinical applications

OBJECTIVE(S): Due to the suitable physical characteristics of (89)Zr as a PET radionuclide and affinity of Trastuzumab monoclonal antibody against HER2, [(89)Zr]Zr-Trastuzumab was prepared and went through preclinical evaluations for ultimate human applications. METHODS: (89)Zr was produced by using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohammadpour-Ghazi, Fatemeh, Yousefnia, Hassan, Divband, GhasemAli, Zolghadri, Samaneh, Alirezapour, Behrouz, Shakeri, Fatemeh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mashhad University of Medical Sciences 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261689/ https://www.ncbi.nlm.nih.gov/pubmed/37324228 http://dx.doi.org/10.22038/AOJNMB.2022.68093.1471

Ejemplares similares

Human Absorbed Dose Estimation of (111)In-DOTA-PR81 as a Novel High Potential Agent for Breast Cancer Imaging
por: Yousefnia, Hassan, et al.
Publicado: (2022)

Evaluation of the Possible Utilization of (68)Ga-DOTATOC in Diagnosis of Adenocarcinoma Breast Cancer
por: Zolghadri, Samaneh, et al.
Publicado: (2018)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Human Dose Assessment of (68)Ga-NODAGA-RGD-BBN Heterodimer Peptide based on Animal Data
por: Amraee, Naeimeh, et al.
Publicado: (2022)

Preparation and evaluation of Lu-(177) phytate Complex for Radiosynovectomy
por: Yousefnia, Hassan, et al.
Publicado: (2014)

(89)Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
por: Chang, Albert J., et al.
Publicado: (2012)

Preclinical Study of (68)Ga-DOTATOC: Biodistribution Assessment in Syrian Rats and Evaluation of Absorbed Dose in Human Organs
por: Naderi, Mojdeh, et al.
Publicado: (2016)

Production and Quality Control of [(67)Ga]-DOTA-trastuzumab for Radioimmunoscintigraphy
por: Alirezapour, Behrooz, et al.
Publicado: (2013)

Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats
por: Yousefnia, Hassan, et al.
Publicado: (2015)

Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation
por: Zolghadri, Samaneh, et al.
Publicado: (2015)

Click-to-Release: Cleavable Radioimmunoimaging with [(89)Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio
por: Vlastara, Maria, et al.
Publicado: (2023)

Development of (166)Holmium-1,2 Propylene Di-amino Tetra (Methy1enephosphonicacid) as a Possible Bone Palliation Agent
por: Zolghadri, Samaneh, et al.
Publicado: (2014)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Synthesis and Feasibility Evaluation of a new Trastuzumab Conjugate Integrated with Paclitaxel and (89)Zr for Theranostic Application Against HER2‐Expressing Breast Cancers
por: Jang, Joo Hee, et al.
Publicado: (2019)

Comparative in vivo biodistribution of cells labelled with [(89)Zr]Zr-(oxinate)(4) or [(89)Zr]Zr-DFO-NCS using PET
por: Friberger, Ida, et al.
Publicado: (2023)

Production, Quality Control and Biological Evaluation of (166)Ho-PDTMP as a Possible Bone Palliation Agent
por: Zolghadri, Samaneh, et al.
Publicado: (2013)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2021)

Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
por: Marquez, Bernadette V., et al.
Publicado: (2014)

Correction: Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2022)

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging
por: McKnight, Brooke N., et al.
Publicado: (2018)

Therapeutic Response Monitoring with (89)Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
por: Kang, Minwoo, et al.
Publicado: (2022)

Development of (89)Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications
por: Lange, Sara E.S., et al.
Publicado: (2016)

Heptadentate chelates for (89)Zr-radiolabelling of monoclonal antibodies
por: Guillou, Amaury, et al.
Publicado: (2022)

Current Perspectives on (89)Zr-PET Imaging
por: Yoon, Joon-Kee, et al.
Publicado: (2020)

First-time imaging of [(89)Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner
por: Brouwers, Adrienne H., et al.
Publicado: (2022)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using (89)Zr-DFO-Trastuzumab
por: Holland, Jason P., et al.
Publicado: (2010)

Pulmonary Tc(99m)-PSMA uptake in asymptomatic COVID-19 patient: incidental finding in SPECT/CT study
por: Kalantari, Forough, et al.
Publicado: (2022)

Evaluation of Candidate Theranostics for (227)Th/(89)Zr Paired Radioimmunotherapy of Lymphoma
por: Abou, Diane S., et al.
Publicado: (2023)

N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by (89)Zr-Trastuzumab and (18)F-FDG PET imaging
por: Wimana, Zéna, et al.
Publicado: (2017)

Annotating MYC oncogene status with (89)Zr-transferrin imaging
por: Holland, Jason P., et al.
Publicado: (2012)

Microfluidic Preparation of (89)Zr-Radiolabelled Proteins by Flow Photochemistry
por: Earley, Daniel F., et al.
Publicado: (2021)

(89)Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
por: Bensch, Frederike, et al.
Publicado: (2018)

PET Imaging of Liposomal Glucocorticoids using (89)Zr-oxine: Theranostic Applications in Inflammatory Arthritis
por: Gawne, Peter J., et al.
Publicado: (2020)

PET Imaging of Small Extracellular Vesicles via [(89)Zr]Zr(oxinate)(4) Direct Radiolabeling
por: Khan, Azalea A., et al.
Publicado: (2022)

(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer
por: Menke-van der Houven van Oordt, Catharina Willemien, et al.
Publicado: (2015)

(89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics
por: Pool, Martin, et al.
Publicado: (2017)

(89)Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations
por: Kahts, Maryke, et al.
Publicado: (2023)

Preparation and Quality Control of (68)Ga-Citrate for PET Applications
por: Aghanejad, Ayuob, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2udf6co600ipoul3a7242c4k9n